Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial
| العنوان: | Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial |
|---|---|
| المؤلفون: | John Changalucha, Mooketsi Molefi, Shabbar Jaffar, Awilly A Chofle, William W. Hope, Gregory P. Bisson, Siprimele F Molloy, Katlego Tsholo, Norah Mawoko, Thomas S. Harrison, Mark W Tenforde, Jeremiah Kidola, David Lawrence, Gabriella Bidwell, Raju K. K. Patel, Tshepo B Leeme, Nametso Tlhako, Joseph N Jarvis, Charles Muthoga |
| المصدر: | CLINICAL INFECTIOUS DISEASES |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Antifungal Agents, 030106 microbiology, HIV Infections, Meningitis, Cryptococcal, Tanzania, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Amphotericin B, Internal medicine, Clinical endpoint, Humans, Medicine, 030212 general & internal medicine, Articles and Commentaries, Cerebrospinal Fluid, Botswana, business.industry, medicine.disease, Confidence interval, Treatment Outcome, Infectious Diseases, Cryptococcus neoformans, Female, Liposomal amphotericin, business, Cryptococcal meningitis, Meningitis, Fluconazole, medicine.drug |
| الوصف: | Background\ud We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.\ud \ud Methods\ud Human immunodeficiency virus (HIV)-infected adults with CM were randomized to (i) L-AmB 10 mg/kg on day 1 (single dose); (ii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses); (iii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses); or (iv) L-AmB 3 mg/kg/day for 14 days (control). All patients also received oral fluconazole 1200 mg/day for 14 days. Primary endpoint was mean rate of clearance of cerebrospinal fluid cryptococcal infection (EFA). Noninferiority was defined as an upper limit of the 2-sided 95% confidence interval (CI) of difference in EFA between intervention and control |
| وصف الملف: | application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| اللغة: | English |
| تدمد: | 1024-8064 1537-6591 1058-4838 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58960376a12a51500aeace8ec383231 http://livrepository.liverpool.ac.uk/3026072/1/e00885-18.full.pdf |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e58960376a12a51500aeace8ec383231 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10248064 15376591 10584838 |
|---|